Research and Markets: Investigation Report on China’s Bevacizumab Market 2010-2019
August 28, 2015 | By Business Wire News
DUBLIN
Research and Markets (http://www.researchandmarkets.com/research/dsgvcp/investigation) has announced the addition of the “Investigation Report on China’s Bevacizumab Market ,2010-2019” report to their offering.
Developed by Roche under the trade name of Avastin, bevacizumab injection is the first angiogenesis inhibitor in the world. In Feb. 26, 2010, it was approved by CFDA to treat metastatic colorectal cancer. Currently, bevacizumab injections available in China all come from Roche and its subsidiary Genectech. In Jul. 2013, Kanion Pharmaceutical’s Establishment of Evaluation System of Traditional Chinese Medicine’s Efficacy in Treating Gastrointestinal Inflammatory Disease as well as Jiangsu Hengrui Medicine Co., Ltd’s Introduction of Monoclonal Antibody Technology and Development of Bevacizumab have been designated by the Ministry of Science and Technology of the People’s Republic of China as Key International S&T Cooperation Projects. In Dec. 2013, phase I clinical trial of the generic drug of bevacizumab co- developed by Huahai Pharmaceutical and Oncobiologics was approved to be conducted in the EU.
Bevacizumab injection developed fast after entering China, with sales value reaching CNY 265 million in 2013 despite a slight decline in 2014 and CAGR during the period of 2010-2014 reaching 126.67%. With improvements in living standards and lifestyle changes, obesity rate in China goes up gradually, which increases the risk of colorectal cancer. Hence the vast demand for bevacizumab injection in China. Currently, the market is monopolized by Shanghai Roche Pharmaceutical Co., Ltd that brought in a sales value of CNY 264 million in 2014. As some local enterprises are trying to make generic drugs of bevacizumab injection, the monopoly of Roche is expected to be broken by local products in the next few years.
Key Topics Covered:
1 Related Concepts of Bevacizumab
2 Market Profile of Bevacizumab in China
3 Survey on Sales Status of Bevacizumab in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Bevacizumab in China, 2010-2014
5 Survey on Dosage Forms of Bevacizumab in China, 2010-2014
6 Reference Price of Bevacizumab in Chinese Hospitals in 2014
7 Major Manufacturers of Bevacizumab in Chinese Market, 2010-2014
8 Market Outlook of Bevacizumab in China, 2015-2019
Companies Mentioned
– Genentech
– Roche
For more information visit http://www.researchandmarkets.com/research/dsgvcp/investigation
View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005584/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Chemicals
